<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85685">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919450</url>
  </required_header>
  <id_info>
    <org_study_id>13-058</org_study_id>
    <nct_id>NCT01919450</nct_id>
  </id_info>
  <brief_title>Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation</brief_title>
  <official_title>Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy M. Bateman, MD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Imaging Technologies</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the consistency of quantitative peak stress
      myocardial blood flow and myocardial blood flow reserve following a 10 second, 2 minute or 4
      minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection.
      It is anticipated that there will be no or minimal difference between the three delay times.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Measure Quantitated Myocardial Perfusion Reserve after a 4 Minute Delay in Lexiscan (Regadenoson)</measure>
    <time_frame>4 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve values based on a 10 second, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Quantitated Myocardial Perfusion Reserve after a 2 Minute Delay in Lexiscan (Regadenoson)</measure>
    <time_frame>2 mintues</time_frame>
    <safety_issue>No</safety_issue>
    <description>The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve values based on a 10 second, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Quantitated Myocardial Perfusion Reserve after a 10 Second Delay in Lexiscan (Regadenoson)</measure>
    <time_frame>10 seconds</time_frame>
    <safety_issue>No</safety_issue>
    <description>The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve values based on a 10 second, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myocardial Blood Flow Reserve</condition>
  <arm_group>
    <arm_group_label>10 Second Delay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Minute Delay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Minute Delay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.</description>
    <arm_group_label>10 Second Delay</arm_group_label>
    <arm_group_label>2 Minute Delay</arm_group_label>
    <arm_group_label>4 Minute Delay</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Rubidium-82</intervention_name>
    <description>Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.</description>
    <arm_group_label>10 Second Delay</arm_group_label>
    <arm_group_label>2 Minute Delay</arm_group_label>
    <arm_group_label>4 Minute Delay</arm_group_label>
    <other_name>Cardio-Gen82</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent normal clinically-indicated exercise myocardial perfusion SPECT, treadmill
             maximal exercise test or exercise echocardiographic study

          -  No change in symptoms between the exercise study and PET study

          -  Capable of providing written informed consent

          -  BMI 25-32 kg/m2

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Coronary Artery Calcium Score &gt;25

          -  Second and Third Degree Atrioventricular Node Block

          -  Sinus Node Dysfunction

          -  Recent Syncope of unknown etiology

          -  Left ventricular hypertrophy per ECG or echocardiography

          -  Slowed circulation times

          -  Active wheezing or with acute asthmatic or bronchospastic attacks requiring changes
             in therapy within the past 30 days.

          -  Patients that have experienced a previous hypersensitivity reaction thought to be
             related to Lexiscan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Imaging Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Staci A Courter, MA</last_name>
    <phone>816-531-2842</phone>
    <phone_ext>107</phone_ext>
    <email>scourter@cvit.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothy M Bateman, MD</last_name>
    <phone>816-751-8542</phone>
    <email>tbateman@cvit.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Luke's Hospital Imaging Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci A Courter, MA</last_name>
      <phone>816-531-2842</phone>
      <phone_ext>107</phone_ext>
      <email>scourter@cvit.com</email>
    </contact>
    <contact_backup>
      <last_name>Timothy M Bateman, MD</last_name>
      <phone>816-751-8542</phone>
      <email>tbateman@cvit.com</email>
    </contact_backup>
    <investigator>
      <last_name>James A Case, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cardiovascular Imaging Technologies</investigator_affiliation>
    <investigator_full_name>Timothy M. Bateman, MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>Lexiscan</keyword>
  <keyword>Regadenoson</keyword>
  <keyword>Rubidium</keyword>
  <keyword>Blood Flow Reserve</keyword>
  <keyword>Myocardial Perfusion</keyword>
  <keyword>Quantitated Myocardial Perfusion</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
